Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Nuformix (NFX) Share Price

Price 0.09p on 12-08-2025 at 18:50:07
Change 0.005p 5.88%
Buy 0.10p
Sell 0.08p
Last Trade: Sell 1,639,262.00 at 0.083p
Day's Volume: 18,482,836
Last Close: 0.09p
Open: 0.085p
ISIN: GB00BYW79Y38
Day's Range 0.085p - 0.0925p
52wk Range: 0.04p - 0.23p
Market Capitalisation: £1.53m
VWAP: 0.085274p
Shares in Issue: 1.70b

Nuformix (NFX) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 1,639,262 0.083p Ordinary
16:29:47 - 12-Aug-25
Unknown* 500,000 0.09p Ordinary
16:04:22 - 12-Aug-25
Buy* 41,748 0.087p Ordinary
14:57:12 - 12-Aug-25
Sell* 4,574,833 0.0835p Ordinary
13:13:28 - 12-Aug-25
Sell* 4,578,818 0.0836p Ordinary
12:39:26 - 12-Aug-25
Buy* 4,548,685 0.0875p Ordinary
11:48:56 - 12-Aug-25
Buy* 30,133 0.09p Ordinary
11:08:22 - 12-Aug-25
Buy* 4,888 0.09p Ordinary
10:57:17 - 12-Aug-25
Buy* 2,000,000 0.0879p Ordinary
10:28:34 - 12-Aug-25
Buy* 564,469 0.088p Ordinary
08:48:36 - 12-Aug-25
See more Nuformix trades

Nuformix (NFX) Share Price History

Time period:
to
Date Open High Low Close Volume
11th Aug 2025 (Mon) 0.095 0.095 0.085 0.085 20,946,711
8th Aug 2025 (Fri) 0.085 0.085 0.085 0.085 9,804,501
7th Aug 2025 (Thu) 0.085 0.085 0.085 0.085 3,236,272
6th Aug 2025 (Wed) 0.08 0.085 0.08 0.085 13,889,933
5th Aug 2025 (Tue) 0.08 0.08 0.08 0.08 8,050,837
4th Aug 2025 (Mon) 0.0775 0.08 0.0758 0.08 3,330,747
1st Aug 2025 (Fri) 0.0775 0.0775 0.0775 0.0775 6,471,394
31st Jul 2025 (Thu) 0.0775 0.0775 0.0775 0.0775 8,508,269
30th Jul 2025 (Wed) 0.0775 0.0775 0.0775 0.0775 7,529,050
29th Jul 2025 (Tue) 0.0825 0.0825 0.075 0.0775 57,485,013
28th Jul 2025 (Mon) 0.0875 0.0875 0.0825 0.0825 26,736,356
25th Jul 2025 (Fri) 0.09 0.0925 0.0875 0.0875 24,087,307
24th Jul 2025 (Thu) 0.0875 0.095 0.085 0.09 49,720,947
23rd Jul 2025 (Wed) 0.08 0.09 0.0775 0.0875 100,721,673
22nd Jul 2025 (Tue) 0.085 0.085 0.08 0.08 36,779,236
21st Jul 2025 (Mon) 0.09 0.09 0.085 0.085 45,681,172
18th Jul 2025 (Fri) 0.085 0.09 0.085 0.09 7,827,759
17th Jul 2025 (Thu) 0.09 0.0875 0.0842 0.0842 25,993,795
16th Jul 2025 (Wed) 0.09 0.095 0.09 0.09 9,317,891
15th Jul 2025 (Tue) 0.095 0.095 0.0875 0.09 30,445,384
14th Jul 2025 (Mon) 0.0975 0.11 0.095 0.095 83,660,229
See more Nuformix price history

Nuformix (NFX) Regulatory News

Date Source Headline
11th Aug 2025 7:00 am RNS US FDA ODD Application Submitted for NXP002
30th May 2025 2:24 pm RNS Total Voting Rights
29th May 2025 7:00 am RNS Confirmation of European ODD for NXP002
23rd May 2025 1:08 pm RNS Publication of a Prospectus
22nd May 2025 7:00 am RNS £210,000 Placing
19th May 2025 7:00 am RNS-R Attendance at American Thoracic Society Congress
2nd May 2025 7:00 am RNS Half-year Report
30th Apr 2025 7:00 am RNS Confirmation of European Orphan Drug Designation
29th Apr 2025 7:00 am RNS Change of Registered Office and Company Secretary
14th Apr 2025 7:00 am RNS Exercise of Warrants
See more Nuformix regulatory news

Nuformix (NFX) Share News

IN BRIEF: Nuformix submits FDA drug designation application for NXP002

11th Aug 2025 12:11

Nuformix PLC - London-based developer of treatments for fibrosis and oncology - Submits US Food & Drug Administration orphan drug designation application for the NXP002 programme in idiopathic pulmonary fibrosis. If the orphan drug designation is granted, Nuformix may be eligible for some benefits, like tax credits for clinical trials or qualified clinical testing costs. Read More

Nuformix shares fall despite EU orphan drug status for lead treatment

29th May 2025 18:21

(Alliance News) - Nuformix PLC on Thursday said its lead programme, NXP002, has been granted orphan drug designation by the European Medicines Agency for the treatment of idiopathic pulmonary fibrosis. Read More

Nuformix interim loss widens as focused on advancing assets

2nd May 2025 12:19

(Alliance News) - Nuformix PLC on Friday said it has continued to "advance and exploit" assets in its portfolio, two days after noting a positive opinion from an EU committee for NXP002. Read More

Nuformix finds positive data for NXP002 in lung fibrosis study

9th Apr 2025 16:29

(Alliance News) - Nuformix PLC on Wednesday said fresh analysis of lung tissue from patients with idiopathic pulmonary fibrosis and autoimmune-related interstitial lung disease showed "positive" results for its lead asset NXP002, supporting its potential in treating a wider range of fibrotic conditions. Read More

UK shareholder meetings calendar - next 7 days

13th Mar 2025 14:41

Read More

See more Nuformix news
FTSE 100 Latest
Value9,147.81
Change18.10

Login to your account

Forgot Password?

Not Registered